<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111419</url>
  </required_header>
  <id_info>
    <org_study_id>IMPRESSION</org_study_id>
    <nct_id>NCT04111419</nct_id>
  </id_info>
  <brief_title>Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation</brief_title>
  <official_title>Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation (IMPRESSION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Study name: Intensive management of blood pressure and cholesterol in elderly Chinese&#xD;
           with hypertension and atrial fibrillation (IMPRESSION)&#xD;
&#xD;
        2. Medicine: amlodipine/atorvastatin (5/10mg tablet); amlodipine/atorvastatin (5/20mg&#xD;
           tablet); allisartan (240mg/tablet).&#xD;
&#xD;
        3. Rationale: controlling blood pressure and cholesterol are both effective means to reduce&#xD;
           cardiovascular risks, however, it is still unknown whether high cardiovascular risk&#xD;
           patients with atrial fibrillation would benefit from intensive management of blood&#xD;
           pressure and cholesterol.&#xD;
&#xD;
        4. Objective: To evaluate the efficacy and safety of intensive management of blood pressure&#xD;
           and cholesterol.&#xD;
&#xD;
        5. Study design: This study is a multi-center, randomized and controlled clinical trial&#xD;
           with four equally sized treatment groups: amlodipine/atorvastatin (5/10mg tablet);&#xD;
           amlodipine/atorvastatin (5/20mg tablet); amlodipine/atorvastatin (5/10mg&#xD;
           tablet)+allisartan (240mg/tablet); amlodipine/atorvastatin (5/20mg tablet)+allisartan&#xD;
           (240mg/tablet).&#xD;
&#xD;
        6. Study population: Men and Women aged over 65 years (n=1200) meeting the&#xD;
           inclusion/exclusion criteria.&#xD;
&#xD;
        7. Randomization and treatment: After stratification by centers, eligible patients will be&#xD;
           randomly divided into four groups, taking amlodipine/atorvastatin (5/10mg tablet) once a&#xD;
           day or amlodipine/atorvastatin (5/20mg tablet) once a day or amlodipine/atorvastatin&#xD;
           (5/10mg tablet)+allisartan (240mg/tablet) once a day or amlodipine/atorvastatin (5/20mg&#xD;
           tablet)+allisartan (240mg/tablet) once a day.&#xD;
&#xD;
        8. Follow up: 3 years.&#xD;
&#xD;
        9. Sample size: a total of 1200 patients should be enrolled in the combination.&#xD;
&#xD;
       10. Timeline: After obtaining the approval of Ethics Committee of Ruijin Hospital in&#xD;
           September 2019, recruitment will start. Patients enrollment will be performed between&#xD;
           November 2019 to November 2020. All patients should be followed up before December 2023.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study name: Intensive management of blood pressure and cholesterol in elderly Chinese&#xD;
           with hypertension and atrial fibrillation (IMPRESSION)&#xD;
&#xD;
        2. Medicine: amlodipine/atorvastatin (5/10mg tablet); amlodipine/atorvastatin (5/20mg&#xD;
           tablet); allisartan (240mg/tablet).&#xD;
&#xD;
        3. Rationale: controlling blood pressure and cholesterol are both effective means to reduce&#xD;
           cardiovascular risks, however, it is still unknown whether high cardiovascular risk&#xD;
           patients with atrial fibrillation would benefit from intensive management of blood&#xD;
           pressure and cholesterol.&#xD;
&#xD;
        4. Objective: To evaluate the efficacy and safety of intensive management of blood pressure&#xD;
           and cholesterol, especially in hypertensive patients with atrial fibrillation.&#xD;
&#xD;
        5. Study design: This study is a multi-center, randomized and controlled clinical trial&#xD;
           with four equally sized treatment groups: amlodipine/atorvastatin (5/10mg tablet);&#xD;
           amlodipine/atorvastatin (5/20mg tablet); amlodipine/atorvastatin (5/10mg&#xD;
           tablet)+allisartan (240mg/tablet); amlodipine/atorvastatin (5/20mg tablet)+allisartan&#xD;
           (240mg/tablet).&#xD;
&#xD;
        6. Study population: Men or women aged over 65 years (n=1200) will be screened for atrial&#xD;
           fibrillation. Atrial fibrillation patients who never took antihypertensive drugs or stop&#xD;
           antihypertensive drugs for more than 2 weeks with systolic blood pressure of 140-179&#xD;
           mmHg and / or diastolic blood pressure of 90-109 mmHg or who is on monotherapy for at&#xD;
           least 2 weeks with systolic blood pressure of 140-179 mmHg and / or diastolic blood&#xD;
           pressure of 90-109 mmHg will be recruited. Before randomization, two visits should be&#xD;
           performed and 6 clinic blood pressures should be recorded. The average of the 6 clinic&#xD;
           blood pressures should be 140-179 mmHg in systolic and/or 90-109 mmHg in diastolic.&#xD;
           Regardless of whether the office blood pressure meets the enrollment conditions, a&#xD;
           one-week home blood pressure measurement should be performed before randomization.&#xD;
           Patient should sign the written consent form before screening and be able to go to the&#xD;
           clinic by him/herself. Exclusion criteria included: suspected or confirmed secondary&#xD;
           hypertension; history of coronary heart disease, myocardial infarction, heart failure,&#xD;
           stroke or dementia; taking other drugs that might affect blood pressure; liver&#xD;
           dysfunction, serum creatinine ≥1.5 mg/dL (133 μmol/L), urine protein positive; serum&#xD;
           potassium &gt;5.0 mmol/L or &lt;3.5 mmol/L; uncontrolled diabetes (HbA1c &gt;8%); BMI ≥35kg/m²;&#xD;
           elderly care patients; or patients who are participating in other clinical trials.&#xD;
&#xD;
        7. Randomization and treatment: After stratification by centers, eligible patients will be&#xD;
           randomly divided into four groups, taking amlodipine (5 mg/tablet)+ once a day or&#xD;
           amlodipine besylate tablets (5 mg/tablet) + hydrochlorothiazide tablets (25 mg/tablet)&#xD;
           once a day.&#xD;
&#xD;
        8. Follow up: Sitting office blood pressures and electrocardiogram should measured by an&#xD;
           OMRON device. Medical history should be recorded. Clinical examinations including home&#xD;
           blood pressure, electrocardiogram, blood and urine routine tests and biochemical tests&#xD;
           should be performed. Patients should be followed up every three months. Before the&#xD;
           follow-up, patients should perform a one-week home blood pressure monitoring.&#xD;
&#xD;
        9. Sample size and statistical analysis: At least 300 eligible patients should be enrolled&#xD;
           in each group, and a total of 1200 patients should be enrolled in total. Data will be&#xD;
           analyzed by using the SAS software. ANOVA will be used to compare the parameters between&#xD;
           groups and the difference between the four groups with the calculation of 95% confidence&#xD;
           interval. In addition, a covariance analysis will also be used in the analysis of&#xD;
           baseline parameters.&#xD;
&#xD;
       10. Timeline: After obtaining the approval of Ethics Committee of Ruijin Hospital in&#xD;
           September 2019, recruitment will start. Patients enrollment will be performed between&#xD;
           October 2019 to October 2020. All patients should be followed up before December 2023.&#xD;
           Database construction and statistical analysis will be conducted at the same time,&#xD;
           appropriate domestic and international conferences will be selected to publish the&#xD;
           research results. The main results will be published in international professional&#xD;
           medical journals.&#xD;
&#xD;
       11. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin&#xD;
           Hospital, Shanghai, China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be randomly divided into four groups, taking amlodipine/atorvastatin (5/10mg tablet) once a day or amlodipine/atorvastatin (5/20mg tablet) once a day or amlodipine/atorvastatin (5/10mg tablet)+allisartan (240mg/tablet) once a day or amlodipine/atorvastatin (5/20mg tablet)+allisartan (240mg/tablet) once a day.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined cardiovascular end-point events</measure>
    <time_frame>3 years</time_frame>
    <description>Fatal and non-fatal stroke, acute MI and cardiovascular death</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Intensive blood pressure and cholesterol control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive blood pressure and routine cholesterol control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine blood pressure and intensive cholesterol control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine blood pressure and cholesterol control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET</intervention_name>
    <description>amlodipine/atorvastatin (5/20mg tablet) once a day</description>
    <arm_group_label>Intensive blood pressure and cholesterol control</arm_group_label>
    <arm_group_label>Routine blood pressure and intensive cholesterol control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET</intervention_name>
    <description>amlodipine/atorvastatin (5/10mg tablet) once a day</description>
    <arm_group_label>Intensive blood pressure and routine cholesterol control</arm_group_label>
    <arm_group_label>Routine blood pressure and cholesterol control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allisartan Isoproxil</intervention_name>
    <description>allisartan (240mg/tablet) once a day</description>
    <arm_group_label>Intensive blood pressure and cholesterol control</arm_group_label>
    <arm_group_label>Intensive blood pressure and routine cholesterol control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Men or women aged over 65 years. patients who never took antihypertensive drugs or stop&#xD;
        antihypertensive drugs for more than 2 weeks with systolic blood pressure of 140-179 mmHg&#xD;
        and / or diastolic blood pressure of 90-109 mmHg or who is on monotherapy for at least 2&#xD;
        weeks with systolic blood pressure of 140-179 mmHg and / or diastolic blood pressure of&#xD;
        90-109 mmHg.&#xD;
&#xD;
        Patient who sign the written consent and are able to go to the clinic by him/herself.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        suspected or confirmed secondary hypertension; taking two or more antihypertensive drugs;&#xD;
        patients who never take antihypertensive drugs with a clinic blood pressure over 180/110&#xD;
        mmHg or treated patients with a clinic blood pressure over 160/100 mmHg or patients with a&#xD;
        home blood pressure below 130/80 mmHg; history of coronary heart disease, myocardial&#xD;
        infarction, heart failure, stroke or dementia; taking other drugs that might affect blood&#xD;
        pressure; liver dysfunction, serum creatinine ≥1.5 mg/dL (133 μmol/L), urine protein&#xD;
        positive; serum potassium &gt;5.0 mmol/L or &lt;3.5 mmol/L; uncontrolled diabetes (HbA1c &gt;8%);&#xD;
        BMI ≥35kg/m²; severe OSAS; patients who are participating in other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiguang Wang, MD, PhD</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>610911</phone_ext>
      <email>jiguang_wang_jgw@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ji-Guang Wang</investigator_full_name>
    <investigator_title>Director of the Shanghai Institute of Hypertension</investigator_title>
  </responsible_party>
  <keyword>intensive management</keyword>
  <keyword>blood pressure</keyword>
  <keyword>blood cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

